[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammation":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,160,0,25,[9,46,80,120,140,164,194,219,241,268,296,316,347,377,426,455,475,499,518,550,575,601,633,653,688],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100430733","natural-history-of-the-human-biological-response-to-environmental-exposure-and-injury-100430733",false,"NCT04888923","Natural History of the Human Biological Response to Environmental Exposure and Injury","Natural History of The Human Biological Response to Environmental Exposure and Injury","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study.\n2. Ability to provide informed consent.\n3. Able to read and speak English\n4. Male or female, aged \\>=18\n5. Able to travel to the NIEHS CRU for study visits or travel to an offsite event or conference.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Not willing to have samples stored for future use.\n2. Current pregnancy or lactation, by participant verbal confirmation.\n3. Any condition that, in the investigator's opinion, places the participant at undue risk for complications associated with required study procedures.\n\nParticipants will be enrolled according to pre-defined host (e.g. disease, genetic, or demographic) or environmental (exposure) characteristics.",true,"ALL","18 Years","90 Years",{"count":22,"type":23},2000,"ESTIMATED","OBSERVATIONAL","Background:\n\nEnvironmental exposures like pollution, diet, and stress can help cause human diseases, or make them worse. Researchers want to better understand how injury and inflammation are caused by these exposures. They want to collect biological and environmental samples and other data. They may use the samples to measure a range of factors, like hormones, toxins, and chemicals. This will help them improve their studies.\n\nObjective:\n\nTo identify and understand how environmental exposures contribute to human disease.\n\nEligibility:\n\nHealthy adults ages 18 and older\n\nDesign:\n\nParticipants will be screened with questions about their health history, demographics, and medicines they take.\n\nParticipants may give blood, hair, stool, saliva, and\u002For urine samples. They may have a skin punch biopsy to collect skin cells. They may give fingernail or toenail clippings. They may give a sample of exhaled breath.\n\nParticipants may give a sputum sample. They will inhale a saline mist and cough mucus into a cup.\n\nParticipants may have their nasal passages brushed, scraped, or washed.\n\nParticipants may give cheek cell samples. They will swish mouthwash and spit it into a cup.\n\nParticipants who produce sperm may give samples.\n\nParticipants may have bronchoscopy to collect fluid. A saline solution will be put into their lung and then suctioned out, washing areas of the lung.\n\nParticipants may have a pelvic or transvaginal ultrasound. They may have lung function tests.\n\nParticipants may collect household dust, urine, or stool at home.\n\nParticipants will complete surveys about their health, diet, and exposures.\n\nParticipation will last for one or more study visits.\n\nParticipants may be contacted in the future to take part in other studies.",[27,28,29],"Inflammation","Normal Controls","Metabolic Disease",[31,29,27,32],"Blood Collection","Natural History","RECRUITING","2026-08-20",{"date":36,"type":37},"2026-08-21","ACTUAL",{"date":39,"type":37},"2021-11-16",{"date":41,"type":23},"2031-12-31",{"name":43,"class":44},"National Institute of Environmental Health Sciences (NIEHS)","NIH",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":45},"100582854","ketone-ester-and-salt-keas-in-older-adults-100582854","NCT06868719","Ketone Ester And Salt (KEAS) in Older Adults","Ketone Supplementation as a Strategy to Reduce the Negative Health Effects of High Dietary Salt in Older Adults","KEAS-O","Inclusion Criteria:\n\n* Between the ages of 60-85\n* Resting blood pressure no higher than 150\u002F90\n* BMI below 35 kg\u002Fm2 (or otherwise healthy)\n* Free of any metabolic disease (diabetes or renal), pulmonary disorders (COPD, severe asthma, or cystic fibrosis), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular)\n* Do not have any precluding medical conditions that prevent participants from exercising (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis) or giving blood (e.g., blood thinners)\n\nExclusion Criteria:\n\n* High blood pressure - greater than150\u002F90 mmHg\n* Obesity (BMI \\> 30 kg\u002Fm2)\n* History of metabolic disease (diabetes or renal disease), pulmonary disorders (e.g., COPD, severe asthma, \\& cystic fibrosis), and cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular).\n* Medical issues that prevent safe exercise (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis)\n* Medical issues that prevent giving blood (e.g., blood thinners).\n* Current smoking, using smokeless tobacco, or vaping (within past 12 months)\n* Current pregnancy","50 Years","85 Years",{"count":57,"type":23},35,"INTERVENTIONAL",[60],"NA","Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs blood pressure control by affecting systemic blood vessels and the kidneys. These changes contribute to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. Salt is particularly deleterious in older adults who are more likely to exhibit salt-sensitive hypertension. However, salt consumption remains high in the United States. Thus, there is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. Limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally, published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans' protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high-dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury\u002Fimpaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could facilitate novel therapeutic targets to combat high salt.",[63,64,65,27,66],"Salt; Excess","Hypertension","Aging","Blood Pressure",[66,68,65,27,69],"Salt","Cardiovascular Disease","2026-08-18",{"date":72,"type":37},"2026-08-19",{"date":74,"type":37},"2025-03-06",{"date":76,"type":23},"2027-12-31",{"name":78,"class":79},"Indiana University","OTHER",{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":58,"phases":89,"briefSummary":90,"conditions":91,"keywords":103,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":45},"100609711","trans-auricular-stimulation-for-postoperative-inflammation-in-spine-surgery-100609711","NCT07218133","Trans-Auricular Stimulation for Postoperative Inflammation in Spine Surgery","TAPIS","Inclusion Criteria:\n\n* Long-segment spinal fusions (defined as constructs spanning at least L2-pelvis for thoracolumbar fusions or C2-T2 for cervical fusions)\n* Ability to undergo a reliable neurologic examination and pain assessments\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years of age\n* Shorter-segment spinal fusions than those described above\n* Undergoing current active cancer therapy\n* Undergoing treatment with immunosuppressive drugs\n* Additional spinal surgery within past 6 months\n* Sustained bradycardia or presence of pacemaker\n* History of substance abuse",{"count":88,"type":23},50,[60],"This study is a randomized controlled trial that will evaluate the effect of non-invasive auricular vagal nerve stimulation on inflammatory markers, glycemic control, postoperative pain, and inflammation-related clinical outcomes after long-segment spinal fusion surgeries when compared to current accepted management.",[92,93,94,95,96,97,98,27,99,100,101,102],"Spinal Fusion","Hyperglycemia","Postoperative Pain Management","Postoperative Care","Spine Disease","Neurologic Deficits","Neurological Disorder","Spine Condition","Spinal (Fusion) Surgery","Cytokine Levels","Spine Fusion",[104,105,106,107,108,109,110,111],"spinal fusion","postoperative pain","glycemic control","inflammation","vagal nerve stimulation","postoperative complications","cytokine","spine surgery","2026-08-17",{"date":70,"type":37},{"date":115,"type":37},"2025-10-08",{"date":117,"type":23},"2027-06",{"name":119,"class":79},"Alexander T. Yahanda",{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":4,"leadSponsor":139,"locationsCount":45},"100087476","immune-cell-response-to-stimuli-100087476","NCT00397280","Immune Cell Response to Stimuli","Innate Immunity Signal Transduction in Human Leukocytes","* INCLUSION CRITERIA:\n* Normal, healthy adult donors as judged by screening questionnaire\n* Nonpregnant\n* Weighing at least 110 lbs\n* 18-65 years of age\n* HIV negative (proof required every 6 months we will conduct test)\\*\n* Hepatitis B surface antigen and hepatitis C serology negative (checked every 6 months we will conduct test)\\*\n\n  * The rationale for HIV and hepatitis viral testing is that chronic viral infection may alter and possibly invalidate our experimental results. HIV and hepatitis results will be confidentially obtained. Testing will be contracted to an external certified laboratory and will be paid for by the study group. Results will be available only to the study doctor\u002FPI (Fessler), the study coordinator, the CRU Director (Garantziotis, LAI), and the donor, with the few caveats that follow\n\nAll positive HIV, hepatitis B, and hepatitis C results will be promptly communicated to the donor by the study doctor\u002FPI or the CRU Director. The participant will be referred to their physician and\u002For to the N.C. Department of Health for confirmatory testing and counseling. As explained in detail in the attached Supplement describing N.C. State Department of Health code will be followed. The state code mandates reporting of positive results along with the participant s name and identifying information to the N.C. Department of Public Health. Upon contracting with the testing laboratory, clarification will be obtained and documented as to whether the contracted laboratory or the study MD will be responsible for reporting positive results to the state to avoid duplication of reporting. Upon receipt of the test results, the N.C. Department of Health will contact the participant to inform them of the positive result, how to find care, how to avoid infecting others, how the newly diagnosed HIV and\u002For hepatitis infection is reported, and the importance of informing their partners at possible risk because of their HIV and\u002For hepatitis infection. If the HIV, hepatitis B, and hepatitis C results are negative, the participant will be not be notified. However, the participant may contact the research study nurse for their results.\n\nHIV and hepatitis B\u002FC test results, non-reactive and reactive, will be documented confidentially by the PI or study coordinator in the subject s file, and kept in a locked file cabinet in the CRU Medical Records Room.In order to document the reporting procedure and the time associated with the reporting process, a document has been created and placed in the study specific manual (Hepatitis B\u002FC and HIV Notification Process for Reactive Results Form)\n\nEXCLUSION CRITERIA:\n\nBy questionnaire:\n\nFeeling ill within the last 24 hours.\n\nAlcohol consumption in the last 24 hours.\n\nVisit to the dentist in the last 24 hours.\n\nA doctor visit for illness or vaccination in the last 2 weeks.\n\nDiarrhea in the last 2 weeks.\n\nRecurrent fever (4 weeks).\n\nPregnant or suspected pregnancy in the last 6 weeks.\n\nBlood or plasma donation that will cause the participant to exceed 550ml of blood in the last 8 weeks.\n\nReceiving a blood donation in the past 12 months.\n\nBleeding disorder.\n\nAnemia.\n\nHeart problems.\n\nInsulin dependent diabetes.\n\nProblems with blood donation.\n\nRisk of or evidence of Creutzfeldt-Jacob Disease in the family.\n\nHIV-positive status, Hepatitis B\u002FC-positive status or other confirmed or suspected immunosuppressive or immunodeficient conditions.\n\nUse of immunosuppressants or other immune-modifying drugs.\n\nUse of selected medications within the preceding 5 days unless the PI or AI receiving the samples states otherwise (NSAIDS\u002Faspirin\u002Ftylenol, antidepressants, antihistamines , corticosteroids, HMG CoA reductase inhibitors, and antihypertensives).\n\nBy exam:\n\nTemperature over 99.5 F.\n\nBlood pressure less than 90\u002F50.\n\nBlood pressure higher than 170\u002F95 mm Hg.\n\nPulse rate less than 50 or greater than 100 beats\u002Fminute.\n\nIf blood donation exceeds 200ml:\n\n* Hematocrit less than 34% for women or less than 36% for men, or greater than 56% for either gender.\n* Patients will be informed of disqualifying vital signs and hematocrit values and advised by trained staff, as appropriate, to seek assistance from their physician.","65 Years",{"count":129,"type":23},750,"This study will investigate the response of immune cells (neutrophils, monocytes) to various signals in the test tube to determine how they sense the signals in the body and what substances they produce in response to them. It will determine how the cells may, under certain circumstances, contribute to inflammation, and will measure substances in the blood plasma (the liquid, non-cellular part of the blood) that might stimulate white blood cells, in order to understand how the blood responds to possible disease-related conditions.\n\nHealthy normal volunteers 18 years of age and older who weigh at least 110 pounds may be eligible for this study. Participants give about 320 milliliters (mL) of blood (about 1 1\u002F3 cups) or less at each donation. They donate no more than once every 8 weeks and no more than six times a year. On some occasions, less than 320 mL of blood may be drawn. The collected blood is separated into its components and specific cells are exposed to substances to examine their response....",[27],[133,134,32],"Inflammatory Response","Lipopolysaccharide","2026-08-15",{"date":70,"type":37},{"date":138,"type":37},"2009-07-13",{"name":43,"class":44},{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":45},"100477875","relationship-of-inflammation-and-pulmonary-function-to-fungal-translocation-in-hiv-100477875","NCT05502653","Relationship of Inflammation and Pulmonary Function to Fungal Translocation in HIV","Relationship of Fungal Translocation, Inflammation, and Pulmonary Function in HIV","RIFFT","Inclusion Criteria:\n\n* Age 18 to 80\n* HIV positive\n* Virally-suppressed on ART for at least 6 months\n* subjects enrolled in Dr. Morris's HLRC Studies STUDY20020151, STUDY19080258, STUDY19060243, STUDY19070181, STUDY19070181, STUDY19050326 OR subjects being seen at the HIV\u002FPACT clinics.\n\nExclusion Criteria:\n\n* Contraindication to pulmonary function testing (i.e., abdominal or cataract surgery within 3 months, recent myocardial infarction, etc.).\n* individuals with clinical or radiographic evidence of another significant pulmonary diagnosis (e.g. interstitial lung disease, active asthma)\n* inflammatory bowel disease\n* pregnancy\n* use of antibiotics in the prior 2 weeks\n* immunomodulators in the prior 6 months\n* unable to perform any study procedures.","80 Years",{"count":150,"type":23},100,"The investigator will study the origin of fungal translocation in HIV, its relationship to the mycobiome, and its relationship to lung function and inflammation. Supported by the preliminary data and published studies, this project is based on the premise that circulating BDG derived from microbial translocation stimulates inflammation and worsens lung function in PWH.\n\nChronic obstructive pulmonary disease (COPD) is a significant public health problem with few therapies that modify disease trajectory. COPD is a leading cause of mortality in the United States associated with increased morbidity and healthcare costs. Long-acting bronchodilators and inhaled corticosteroids are mainstays of therapy that control symptoms and reduce acute exacerbation frequency, but do not have a significant impact on mortality or lung function trajectory. The National Heart, Lung, and Blood Institute's COPD National Action Plan focuses on the critical need for research to characterize COPD risk factors and disease mechanisms in order to improve the understanding of causes and progression of disease. The ultimate goal is to provide precision therapy to appropriate patient subgroups to preserve health or arrest disease progression.\n\nMicrobial organisms in the gut may have a profound effect on lung disease. The role of the gut-lung axis, defined as the cross-talk between gut microbiota and the lungs, in the pathogenesis of chronic respiratory diseases is emerging as an area of interest. Perturbations of gut microbiota characterized by low microbial diversity and changes in microbiota abundance are linked to childhood asthma risk, airflow obstruction in adult asthma, and severe lung dysfunction in cystic fibrosis. Studies in animals show that both a high fiber diet that modulates gut microbiota and an abundance of beneficial bacterial strains attenuate inflammation, emphysema, and COPD development in response to cigarette smoke exposure in murine models. In humans, recent investigations show differences in the gut microbial communities between COPD patients and healthy individuals as well as shifts in the gut microbiome with acute exacerbations of COPD.",[153,27,154],"HIV Infections","COPD","2026-08-12",{"date":157,"type":37},"2026-08-14",{"date":159,"type":37},"2022-09-01",{"date":161,"type":23},"2027-11-01",{"name":163,"class":79},"University of Pittsburgh",{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":148,"enrollmentInfo":172,"targetDuration":4,"studyType":58,"phases":174,"briefSummary":176,"conditions":177,"keywords":180,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":45},"100628463","phase-2-cortishock-p-trial-of-corticosteroids-in-inflammation-enriched-heart-failure-cardiogenic-shock-100628463","NCT07461961","CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock","CORTISHOCK-P: A Randomized Pilot Trial of Corticosteroids as a Pharmacologic Adjunct to Temporary Mechanical Circulatory Support in Inflammation-Enriched Heart Failure Cardiogenic Shock","CORTISHOCK-P","Inclusion Criteria:\n\nAge ≥ 18 and ≤ 80 years.\n\nHospitalized in the Intensive Care Unit (ICU).\n\nCardiogenic shock defined by clinical and hemodynamic criteria.\n\nHypotension defined by SBP \\\u003C90 mmHg for \\>30 min, MAP \\\u003C60 mmHg for \\>30 min, or requirement of vasopressors to maintain SBP ≥90 mmHg or MAP ≥60 mm Hg.\n\nHypoperfusion defined by altered mental state, cold extremities, livedo reticularis, urine output \\\u003C30 mL\u002Fh, or lactate ≥2 mmol\u002FL.\n\nIf invasive hemodynamic monitoring is available, CI \\\u003C2.2 L\u002Fmin\u002Fm2.\n\nSCAI stage B or stage C at the time of screening.\n\nFor SCAI Stage B (Beginning Shock), clinical evidence of hemodynamic instability (including relative hypotension, a decline in SBP of ≥20-30 mmHg, or MAP \\\u003C20% from baseline, or tachycardia) without hypoperfusion (normal lactate).\n\nFor SCAI Stage B, hypotension SBP \\\u003C90 mmHg or MAP \\\u003C60 mmHg or \\> 30 mmHg drop from baseline, or tachycardia heart rate ≥100 bpm.\n\nFor SCAI Stage C, requiring only one vasoactive\u002Finotrope and\u002For IABP from admission with CS until randomization, AND Vasoactive-inotropic score (VIS) \\\u003C40.\n\nFor SCAI Stage C, NONE of the following criteria of deterioration from admission until randomization: failure to respond to initial single vasopressor\u002Finotrope drug and addition of a second drug, or failure to respond to IABP and need for new MCS device.\n\nFor SCAI Stage C, use of vasoactive agents at the time of randomization must not show: low starting dose with escalation, intermediate starting dose without escalation or de-escalation, or high starting dose with de-escalation.\n\nFor SCAI Stage C, worst lactate 2 - 5 mmol\u002FL and increase ≥ 100% from baseline lactate ≥ 2mmol\u002FL or worst lactate ≥5mmol\u002FL.\n\nDocumented history of chronic heart failure with reduced ejection fraction (LVEF \\\u003C40%).\n\nEtiology of cardiogenic shock must be congestive heart failure decompensation (HF-CS).\n\nhsCRP ≥20 mg\u002FL, reflecting a pro-inflammatory state.\n\nLess than 48 hours since admission\n\nExclusion Criteria:\n\nCardiogenic shock caused by acute myocardial infarction (AMI-CS).\n\nOther special conditions causing cardiogenic shock, including post-cardiotomy CS, peripartum, adrenergic, valvular, restrictive, post-embolic, conduction or rhythm disorders, or related to cardiotropic drug intoxication.\n\nCirculatory shock of another cause, such as septic, hemorrhagic, or anaphylactic shock.\n\nShock post-cardiac arrest.\n\nOnset of cardiogenic shock \\>48 hours.\n\nSCAI stage A, D, or E at the time of enrollment.\n\nSevere hyperglycemia at baseline, defined as blood glucose ≥300 mg\u002FdL despite insulin therapy.\n\nOngoing uncontrollable infection, suspected concomitant sepsis, or mixed septic-cardiogenic shock.\n\nIschemic hepatitis or ALT \\>500 IU\u002FL due to causes other than suspected hypoperfusion.\n\nSevere refractory acute kidney injury (AKI) at baseline, defined as new persistent anuria (urine output \\\u003C50 mL\u002Fday) or refractory AKI requiring new emergent renal replacement therapy.\n\nKnown allergy to methylprednisolone or other steroid analogues.\n\nCardiac transplant patient or on the transplant list.\n\nPatient planned for implantation of a durable LVAD.\n\nMoribund patients (SAPS2 \\>90) or predicated mortality \\>90% within 30 days.\n\nSigns of extremis, including lactate \\>5 mmol\u002FL, pH \\\u003C7.2, or refractory shock requiring escalation to \\>3 vasopressors at screening.\n\nPregnant woman, parturient, or breastfeeding mother.\n\nAdult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice).",{"count":173,"type":23},30,[175],"PHASE2","This pilot study investigates whether giving a short course of intravenous corticosteroids (methylprednisolone) alongside standard medical care can help patients recovering from heart failure-related cardiogenic shock. Heart failure-related cardiogenic shock happens when chronic heart dysfunction causes poor blood circulation and congestion throughout the body. Often, this condition triggers severe inflammation, making it harder for the heart and other organs to recover, even when temporary mechanical heart pumps are used to support blood flow.\n\nThe study aims to see if reducing this inflammation with corticosteroids is safe and can help patients get better faster. Researchers will enroll 30 adult patients hospitalized with early-stage (SCAI Stage B or C) cardiogenic shock related to heart failure. To participate, patients must also show high levels of inflammation in their blood, specifically a high-sensitivity C-reactive protein (hsCRP) level of 20 mg\u002FL or higher\n\nParticipants will be randomly assigned by chance to one of two groups. One group will receive the standard of care alone. The other group will receive the standard of care plus a 7-day course of intravenous methylprednisolone.\n\nThe main goal of the study is to measure the change in inflammation levels (hsCRP) over 7 days. Researchers will also monitor how well the patients' organs recover, track their need for blood pressure medications or mechanical heart pumps, and monitor for any side effects to ensure the treatment is safe",[178,179,27],"Cardiogenic Shock","Heart Failure",[181,182,107,183],"cardiogenic shock","heart failure cardiogenic shock","corticosteroids","NOT_YET_RECRUITING","2026-08-11",{"date":187,"type":37},"2026-08-13",{"date":189,"type":23},"2026-10-01",{"date":191,"type":23},"2029-02-01",{"name":193,"class":79},"Brigham and Women's Hospital",{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":58,"phases":203,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":45},"100599091","effects-of-freeze-dried-grape-powder-on-immune-profiles-in-healthy-aging-adults-100599091","NCT07079982","Effects of Freeze-dried Grape Powder on Immune Profiles in Healthy Aging Adults","Inclusion Criteria:\n\n* 50-75 years old (at time of screening)\n* Body mass index (BMI) 18.5 to \\\u003C 30 kg\u002Fm2\n* Willing to consume grape and control powder during study periods, and refrain from eating grapes and certain other polyphenol-rich foods and beverages during the study\n* Do not fit any exclusion criteria\n\nExclusion Criteria:\n\n* \\\u003C50 years old and \\>75 years old\n* BMI \\\u003C18.5 and ≥ 30 kg\u002Fm2 or body weight \\\u003C 110 pounds\n* Experienced \\>10% weight change in the past 4 weeks\n* Elevated fasting glucose levels (fasting glucose higher than 126 mg\u002FdL) and triglycerides greater than 500 mg\u002FdL\n* Self-reported and\u002For physician-diagnosed history of diabetes mellitus, coronary heart disease, stroke, renal or liver disease, cancer, eating disorders, certain severe and\u002For relapsing\u002Fremitting autoimmune, inflammatory, or metabolic diseases, chronic infections, scleroderma, blood clotting disorders, intravenous drug use, or current pregnancy or lactation\n* Allergy to grapes or any ingredients in the grape or control powders\n* Implanted medical device (e.g., pacemaker) or other health condition that would prevent measurement of body composition by bioelectrical impedance\n* Currently taking lipid-lowering medications (e.g., statins, fibrates), glucose-regulating medications, anti-inflammatory medications (e.g., non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids), or medications that primarily affect blood clotting (e.g., warfarin), long-term antibiotics in the last 3 months, active use of probiotics during the intervention\n* Active smoker","75 Years",{"count":202,"type":23},28,[60],"The purpose of this study is to investigate the effects of consuming grape powder on immune profiles in healthy middle- and older-aged individuals. Specifically, the investigators are interested in evaluating the potential effects of grapes in influencing markers of immune function, inflammation, and metabolism that are known to change with aging. Grapes contain several nutrients and antioxidant polyphenols such as resveratrol, quercetin, vitamin K and fiber, which are known to promote heart and immune health. However, the effects of grapes on altering immune profiles within the context of aging is not well understood. Therefore, this study will explore how daily grape consumption impacts certain markers of immunity in healthy middle- and older-aged adults.\n\nThe main study procedures include consumption of a freeze-dried grape powder and control powder (which tastes the same but has none of the grape compounds that are being studied) mixed with water as a beverage on a daily basis for 4 weeks each. The investigators will additionally ask that participants avoid eating grapes and certain other antioxidant\u002Fgrape-related foods and beverages throughout the 13-week study. Participants will additionally be asked to complete surveys about their diet, physical activity, and medical history, as well as provide blood samples and body weight measures throughout the course of the study. Participation in the study is expected to last about 6.25 hours over the course of 13 weeks and will include 7 visits.",[206,27],"Healthy Aging",[208,209,27,210],"Grapes","Healthy aging","Immune profiles","2026-08-10",{"date":155,"type":37},{"date":214,"type":37},"2025-07-25",{"date":216,"type":23},"2027-09",{"name":218,"class":79},"University of Connecticut",{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":18,"minAge":225,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":229,"conditions":230,"keywords":232,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":4,"leadSponsor":239,"locationsCount":45},"100099544","diagnosis-and-management-of-inflammatory-and-infectious-diseases-100099544","NCT00557726","Diagnosis and Management of Inflammatory and Infectious Diseases","* INCLUSION CRITERIA:\n\n  1. Known or suspected exposure to infection, as determined by the Principal Investigator OR Presence of signs and symptoms of an infectious or inflammatory disease\n  2. Age range: 3 years of age and older.\n  3. NIAID\u002FLIR investigator who has an interest in the patient s illness and is willing to serve as attending physician to supervise the patient's medical care at the NIH.\n  4. Primary physician outside the NIH\n  5. The patient or the patient's Legally Authorized Representative is capable of informed consent and signs the consent form. The consent form will be signed by parents or guardians of patients under the age of 18\n\nEXCLUSION CRITERIA:\n\n1. Pregnant.\n2. Presence of conditions that, in the judgment of the investigator, may put the participant at undue risk or make them unsuitable for participation in the study.","3 Years","100 Years",{"count":228,"type":23},400,"This protocol is being established to cover the evaluation of patients with inflammatory and\u002For infectious diseases which are not covered under previously existing protocols. The purpose of such a protocol is that frequently patients are referred to us with either diagnosed or undiagnosed illnesses which would be of interest to our teaching program or which would serve as a source of patients to subsequently be entered into established, ongoing protocol studies. Such patients will be admitted to the protocol and handled according to accepted medical practice of diagnosis and treatment.",[231,27],"Infection",[27,231,233,32],"Fever","2026-08-06",{"date":236,"type":37},"2026-08-07",{"date":238,"type":37},"1978-02-17",{"name":240,"class":44},"National Institute of Allergy and Infectious Diseases (NIAID)",{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":58,"phases":249,"briefSummary":250,"conditions":251,"keywords":256,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":267},"100650142","assessment-of-the-impact-of-repeated-ischemic-preconditioning-episodes-on-hemodynamic-and-metabolic-parameters-in-patients-at-various-stages-of-chronic-kidney-disease-100650142","NCT07746102","Assessment of the Impact of Repeated Ischemic Preconditioning Episodes on Hemodynamic and Metabolic Parameters in Patients at Various Stages of Chronic Kidney Disease","Inclusion Criteria:\n\n* obtaining the patient's voluntary, informed consent to participate in the experiment,\n* chronic kidney disease in stages G1-G5,\n* women and men over 18 years of age.\n* failure to meet the qualification criteria for participation in the study,\n* consciousness disorders,\n* heart failure (NYHA IV),\n* severe anemia (Hb concentration\\\u003C8g\u002FdL),\n* features of muscle cell damage (e.g. rhabdomyolysis),\n* peripheral circulation disorders, peripheral vascular diseases.\n\nExclusion Criteria:\n\n\\-",{"count":248,"type":23},60,[60],"The aim of our study is to evaluate the impact of repeated episodes of ischemic quenching on changes in blood pressure, heart rate and laboratory parameters of inflammation in patients with kidney diseases. There is credible evidence that intentionally producing periods of ischemia provides protection of the myocardium and blood vessels against subsequent ischemic injury. The examination will be performed during hospitalization in the Department of Nephrology, Hypertension, Transplantology and Internal Diseases and will last 4 days. On the first day, blood pressure will be measured using an automatic blood pressure monitor, radial artery pulse, blood saturation will be measured using a pulse oximeter, and approximately 6 ml of venous blood will be collected from the elbow bend area for laboratory tests. Then, compression of the lower limb below the knee will be performed using a blood pressure cuff. Four 5-minute cycles of inflation and deflation of the cuff will be performed. The pressure on the lower limb will be repeated on the next two days. On the last day of the examination, blood pressure, heart rate and blood saturation will be measured again, and approximately 6 ml of venous blood will be collected again for laboratory tests.",[252,253,254,255,27],"Hemodialysis","Ischemia Preconditioning","Chronic Kidney Disease","Blood Pressure Disorders",[252,257],"ischemia preconditioning","2026-08-03",{"date":260,"type":37},"2026-08-04",{"date":262,"type":23},"2026-07-23",{"date":264,"type":23},"2026-12-31",{"name":266,"class":79},"Medical University of Lodz",2,{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":58,"phases":276,"briefSummary":277,"conditions":278,"keywords":282,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":45},"100639675","phase-2-effect-of-an-isolevuglandin-scavenger-on-salt-sensitivity-of-blood-pressure-and-immune-cell-activation-in-humans-100639675","NCT07602166","Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans","Inclusion Criteria:\n\n* We will perform analyses in participants previously phenotyped for SSBP, defined as a change in systolic blood pressure ≥10 mmHg from salt-loading to salt-depletion,\n* Over 18 years of age. Able to give informed consent,\n\nExclusion criteria:\n\n* Salt-resistant people,\n* Acute cardiovascular event(s) within the previous 6 months,\n* inability to understand the nature, scope, and possible consequences of the study or to participate in\u002Fcomply with the protocol,\n* Current excessive alcohol or illicit drug use,\n* BP below the inclusion criteria levels after discontinuation of therapy,\n* Concomitant diabetes mellitus, type I or II,\n* Autoimmune disease,\n* Recent vaccination,\n* Younger or older than inclusion criteria,\n* Pregnant or breastfeeding\n* Women of childbearing potential unwilling to use highly effective contraceptive (see Risk section),\n* Confirmed or suspected renal, renovascular or endocrine causes of secondary hypertension,\n* Treatment with agents known to increase BP (e.g., adrenergic agonists for ADHD, SSRI and SNRI antidepressants, chronic use of decongestants or non-steroidal anti-inflammatory drugs,\n* Active or ongoing infection, including HIV\u002FAIDS,\n* Active or ongoing malignancy with the exception of basal cell carcinoma of the skin,\n* Severe psychiatric disorders,\n* Any condition that may alter the immunological results of the study including rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, giant cell arteritis, psoriasis, inflammatory bowel disease, and multiple sclerosis,\n* Use of glucocorticoids, immunosuppressants, direct immunomodulators or chemotherapeutic drugs that in the judgment of the investigators may include a major inflammatory component,\n* Individuals who have contraindications to high salt diets (e.g. heart, renal, or liver failure) or low salt diets (e.g. postural orthostatic tachycardia syndrome, prescribed salt tablets, fludrocortisone or midodrine) or 24-hr ambulatory blood pressure monitoring (e.g. women with bilateral upper extremity lymphedema following breast cancer surgeries),\n* Prior diagnosis of liver cirrhosis or the following abnormal liver function studies: AST or ALT \\>1.5x the upper limit of normal or total bilirubin ≥1.5 mg\u002Fdl,\n* Use of Aspirin,\n* Use of monoamine oxidase inhibitors (MAO-I),\n* Individuals with medical contraindications to certain food content,\n* Use of nitrate therapy. (Participants who are taking PDE-5 inhibitors will be instructed to discontinue use at least 48 hours prior to testing),\n* Patients with resistant hypertension, defined as above-goal blood pressure despite the concurrent use of three antihypertensive drug classes at screening, will be excluded for safety reasons,\n* Average of three office-based blood pressure readings greater than 160 mmHg systolic or 100 mmHg diastolic will not be eligible for enrollment,\n* Use of drugs such as anticoagulants (e.g., warfarin), beta-blockers, antiarrhythmics, antidepressants\u002Fantipsychotics, and other medications primarily metabolized by CYP2C9, CYP2C19, and CYP2D6 that may cause drug-drug interaction.",{"count":275,"type":23},20,[175],"Hypertension is the leading cause of preventable deaths globally, driven by complications such as myocardial infarction, stroke, heart failure, and kidney disease. Recent updates in hypertension classification by the American Heart Association (AHA) place nearly half of the U.S. population in the hypertensive category. Excess dietary salt is a major risk factor for hypertension, with 50% of hypertensive individuals exhibiting salt-sensitivity of blood pressure (SSBP). SSBP is an independent predictor of cardiovascular events and death. While kidney mechanisms in salt-sensing have been extensively studied, emerging evidence suggests that immune cells can also sense sodium (Na+).\n\nThis trial hypothesizes that myeloid cell-derived isolevuglandins (IsoLGs) drive endothelial dysfunction, perpetuating the salt-sensitive phenotype. Preliminary data indicate that targeting IsoLGs with the IsoLG scavenger 2-hydroxybenzylamine (2-HOBA) may interrupt this immune-vascular axis, reducing salt sensitivity and associated cardiovascular risks.\n\nThis phase 2 clinical trial aims to investigate the role of 2-HOBA in modulating immune cell function within blood vessels in hypertensive patients. The study will explore the impact of immunity on salt sensitivity and assess 2-HOBA's potential to reduce endothelial dysfunction, improve immune cell activation, and alleviate SSBP.",[279,280,27,281],"Salt Sensitivity of Blood Pressure","High Blood Pressure","Renin-Angiotensin-Aldosterone System",[283,284,285,286],"salt sensitivity","hypertension","renin-angiotensin-aldosterone system","immune cells","2026-07-24",{"date":289,"type":37},"2026-07-28",{"date":291,"type":23},"2026-09",{"date":293,"type":23},"2031-07",{"name":295,"class":79},"Vanderbilt University Medical Center",{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":200,"enrollmentInfo":303,"targetDuration":4,"studyType":58,"phases":304,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":312,"leadSponsor":314,"locationsCount":45},"100634026","phase-2-disulfiram-in-rheumatoid-arthritis-100634026","NCT07534332","Disulfiram in Rheumatoid Arthritis","Therapeutic Targeting of Gasdermin D-Mediated Pyroptosis to Attenuate Joint Inflammation in Rheumatoid Arthritis","Inclusion Criteria:\n\nAge 18-75 years Body mass index (BMI) ≥25 kg\u002Fm² Diagnosis of rheumatoid arthritis (RA) according to ACR\u002FEULAR classification criteria Active disease defined as Clinical Disease Activity Index (CDAI) \\>10 Stable disease-modifying antirheumatic drug (DMARD) therapy for ≥3 months prior to enrollment Willingness to abstain from alcohol for the duration of the study Ability and willingness to comply with study procedures\n\n\\-\n\nExclusion Criteria:\n\nSignificant liver dysfunction (ALT or AST \\>2.5× upper limit of normal) Current or recent alcohol dependence (based on screening, e.g., AUDIT) Known hypersensitivity to disulfiram or other thiuram derivatives Pregnancy or breastfeeding Severe cardiovascular disease (e.g., myocardial infarction, arrhythmia, coronary occlusion) Severe psychiatric illness (e.g., psychosis, suicidal ideation) Neurologic disorders (e.g., epilepsy, peripheral neuropathy, cerebral damage) Chronic or acute renal disease (e.g., nephritis) Hepatic cirrhosis or hepatic insufficiency Use of contraindicated medications (e.g., metronidazole, phenytoin, paraldehyde, alcohol-containing preparations, warfarin) Other autoimmune diseases or active\u002Fchronic infections Diabetes mellitus or hypothyroidism Allergy to topical iodine Any condition that, in the opinion of the investigator, would pose undue risk or interfere with study participation",{"count":275,"type":23},[175],"Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and systemic immune activation. Obesity is common among individuals with RA and is associated with increased disease activity, reduced treatment response, and worse functional outcomes. Inflammation in adipose tissue, driven in part by activation of the NLRP3 inflammasome and downstream gasdermin D (GSDMD)-mediated pathways, may contribute to systemic inflammation and RA disease severity.\n\nDisulfiram (DSF), an FDA-approved medication for alcohol use disorder, has recently been identified as an inhibitor of GSDMD-mediated inflammatory signaling and pyroptosis. Preclinical studies suggest that DSF reduces inflammasome activation, inflammatory cytokine release, and metabolic dysfunction.\n\nThis study is a 12-week, randomized, double-blind, placebo-controlled pilot trial designed to evaluate the safety, tolerability, and preliminary efficacy of DSF in overweight and obese adults with active RA despite stable disease-modifying antirheumatic drug (DMARD) therapy. Participants will be randomized to receive either DSF (250 mg daily) or placebo.\n\nThe primary objective is to assess safety and tolerability. Secondary and exploratory objectives include evaluating the effects of DSF on systemic inflammation, RA disease activity, metabolic parameters, and adipose tissue inflammasome activation. Findings from this study will inform the feasibility and design of larger clinical trials targeting GSDMD-mediated inflammation in RA.",[307,27,308],"Rheumatoid Arthritis","Obesity",{"date":310,"type":37},"2026-07-27",{"date":291,"type":23},{"date":313,"type":23},"2028-04-30",{"name":315,"class":79},"University of Oklahoma",{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":18,"minAge":324,"maxAge":325,"enrollmentInfo":326,"targetDuration":4,"studyType":58,"phases":328,"briefSummary":330,"conditions":331,"keywords":333,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":346},"100354042","phase-4-innovative-steroid-treatment-to-reduce-asthma-development-in-children-after-first-time-rhinovirus-induced-wheezing-100354042","NCT03889743","Innovative Steroid Treatment to Reduce Asthma Development in Children After First-time Rhinovirus Induced Wheezing","Innovative Steroid Treatment to Reduce Asthma Development in Children After First-time Rhinovirus Induced Wheezing - the INSTAR Study","INSTAR","Inclusion Criteria:\n\n* admitted to pediatric acute wards in the participating hospitals in Norway, Finland, Sweden.\n* referred for first severe wheezing episode, defined as first-time acute breathing difficulty with wheezing ever, appearing less than 7 days from onset of symptoms\n* one or more of the following:(a) fever, (b) hypoxia (SAT O2 \\\u003C= 92%), (c) retractions (inter-, subcostal), (d) prolonged expiration (on auscultation), (e) expiratory rhonchi (on auscultation)\n* evidence of rhinovirus infection by PCR-test in nasopharyngeal secretions\n* signed informed consent and expected cooperation of the patients for the treatment and follow-up must be obtained and documented according to ICH GCP, and national\u002Flocal regulations.\n\nExclusion Criteria:\n\n* previous episodes with wheezing, defined as a history of acute breathing difficulty with wheezing in need of treatment at a general practitioner or at hospital, or parental information about similar breathing difficulties\n* gestational age \\\u003C37 weeks\n* chronic illness other than atopy (eczema),\n* previous systemic or inhaled corticosteroid treatment,\n* participation to another trial,\n* varicella infection or contact during the last 2-3 weeks,\n* need for intensive care unit treatment during the present infection, except for respiratory support with non-invasive methods (high flow nasal cannula ventilation, CPAP or BiPAP),\n* any reason why, in the opinion of the investigator, the patient should not participate (e.g. not able to comply with study procedures).\n* COVID-19 related disease.","3 Months","23 Months",{"count":327,"type":23},280,[329],"PHASE4","The overall objective of the study is to determine the efficacy of corticosteroids in preventing recurrent wheezing and asthma in high-risk, first-time severe wheezing children with rhinovirus infection, stratified by rhinovirus genome load.\n\nThe secondary objectives are to determine duration and severity of each acute episode with acute expiratory breathing difficulty, the number of episodes with acute expiratory breathing difficulty, degree of pulmonary hyperreactivity and quality of life within 24 months after study entry.",[332,27],"Asthma",[334,335,336],"Respiratory Sounds","Steroids","Rhinovirus","2026-07-16",{"date":339,"type":37},"2026-07-20",{"date":341,"type":37},"2019-05-08",{"date":343,"type":23},"2028-05",{"name":345,"class":79},"St. Olavs Hospital",8,{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":17,"sex":18,"minAge":355,"maxAge":356,"enrollmentInfo":357,"targetDuration":4,"studyType":58,"phases":358,"briefSummary":359,"conditions":360,"keywords":363,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":45},"100643987","independent-and-combined-effects-of-short-term-sulforaphane-supplementation-and-exercise-on-immunometabolism-in-healthy-adults-100643987","NCT07668596","Independent and Combined Effects of Short-term Sulforaphane Supplementation and Exercise on Immunometabolism in Healthy Adults","Independent and Combined Effects of Short-term Sulforaphane Supplementation and Exercise on Immunometabolism in Healthy Adults: A Randomized Crossover Study","EXSFN","Inclusion Criteria:\n\n* aged between 19 and 35 years\n* not a current smoker\n* physically active based on the Canadian Physical Activity Guidelines (150 minutes of weekly physical activity)\n\nExclusion Criteria:\n\n* a history of cardiometabolic diseases or respiratory diseases (e.g., chronic obstructive pulmonary disease, asthma, diabetes, coronary artery disease)\n* currently following a ketogenic diet\n* body mass index (BMI) over 30 kg\u002Fm2\n* unable to read or communicate in English\n* having received a vaccination or experienced an upper respiratory tract infection in the last 4 weeks\n* having donated more than 0.5 L of blood within the last 4 weeks\n* currently pregnant\n* have contraindications to high intensity exercise (assessed using the CSEP Get Active Questionnaire)","19 Years","35 Years",{"count":275,"type":23},[60],"The study consist of 3 interventional periods which will be completed by each consenting participant in a randomized, crossover fashion. The interventional periods will be separated by a minimum 1 week washout period. One of the interventions consists of 4 days of daily supplementation with the commercially available broccoli sprout extract capsules (BrocElite). Another intervention will consist of 4 days of daily supervised treadmill running. The exercise protocol consists of 4 minutes of high-intensity running running followed by a 3 minute recovery period, repeated for a total of 4 repetitions. The last intervention combines the above two and consists of 4 days of daily supplementation and daily supervised exercise training. Before and after each intervention, basic anthropometrics (weight, heart rate, and blood pressure) will be recorded, and a venous blood sample will be collected. Blood samples will be analyzed for metabolic and inflammatory markers. Participants will be asked to refrain from structured exercise, alcohol consumption, and broccoli consumption during each of the experimental periods. Before any testing, willing participants will provide informed consent, and fill out a few demographic, and lifestyle questionnaires. The study will be conducted at the University of British Columbia in Kelowna, BC, Canada.",[361,362,27],"Immunometabolism","Mitochondrial Function, Bioenergetics",[364,365,366,361,27,367],"Nutraceuticals","Exercise","Bioenergetics","High intensity interval training","2026-07-15",{"date":370,"type":37},"2026-07-17",{"date":372,"type":37},"2026-03-01",{"date":374,"type":23},"2028-06-01",{"name":376,"class":79},"University of British Columbia",{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":384,"enrollmentInfo":385,"targetDuration":4,"studyType":58,"phases":387,"briefSummary":388,"conditions":389,"keywords":392,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":45},"100647913","short-chain-fatty-acids-in-lypopolysaccharide-induced-inflammation-and-executive-function-100647913","NCT07713641","Short-Chain Fatty Acids in Lypopolysaccharide-Induced Inflammation and Executive Function","Investigating the Role of Short-Chain Fatty Acids in Endotoxemia-Induced Inflammation and Core Executive Functioning: A Randomized, Triple-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Voluntary written informed consent obtained prior to any study procedure\n* Healthy, with no gastrointestinal or psychological complaints\n* Age 18-45 years\n* BMI 18.5-27 kg\u002Fm2\n* Proficiency in English and\u002For Dutch\n\nExclusion Criteria:\n\n* History of previous or current neurological disorder (e.g., epilepsy, multiple sclerosis, migraine with aura)\n* History of previous or current psychiatric disorder (e.g., depression, anxiety disorders, bipolar disorder, schizophrenia)\n* History of previous or current gastrointestinal disorder (e.g., Crohn's disease, ulcerative colitis, irritable bowel syndrome)\n* History of previous or current endocrine disorder (e.g., diabetes, thyroid disorders, polycystic ovary syndrome)\n* History of immune system disorder, including inflammatory, autoimmune, or severe allergic conditions (e.g., rheumatoid arthritis, lupus, celiac disease, or severe allergies such as anaphylaxis)\n* History of neuropsychiatric disorder (e.g., ADHD, autism spectrum disorder, learning disorder, Tourette's syndrome)\n* History of major head trauma (e.g., concussion with loss of consciousness or long-term symptoms)\n* History of severe infection (e.g., sepsis, pneumonia requiring hospitalization, meningitis, endocarditis, or other systemic infection requiring hospitalization, intravenous antibiotics, or intensive care)\n* One or more diagnoses based on the Mini International Neuropsychiatric Interview (MINI)\n* One or more diagnoses based on ROME-IV criteria for gastrointestinal disorders\n* Any disorder that, in the investigator's opinion, might jeopardise the participant's safety or compliance with the protocol\n* Any prior or concomitant treatment that might jeopardise the participant's safety or compromise the integrity of the study\n* Participation in an interventional trial with an investigational medicinal product (IMP) or device\n* Current or recent (past month) prescribed medication use, with particular attention to cardiovascular drugs, steroids, NSAIDs, and centrally-acting drugs (excluding isolated over-the-counter use such as ibuprofen or paracetamol, and hormonal contraceptives in women)\n* Use of psychotropic medication within the past year (e.g., antidepressants, anxiolytics, antipsychotics)\n* Use of antibiotics within three months preceding the study\n* Use of pre- or probiotics within one month preceding the study\n* Current or recent (past month) infection (e.g., common cold, influenza, COVID-19)\n* Recent (past month) vaccination\n* Pregnant or lactating women\n* Previous or current substance or alcohol dependence or abuse (\\>2 units\u002Fday or \\>14 units\u002Fweek)\n* Smoking\n* Night-shift work\n* Adherence to special diets (e.g., vegan, vegetarian, weight-loss, lactose-free, gluten-free)\n* Previous experience with or knowledge of any of the cognitive tasks used in the study (questionnaires excluded)\n* C-reactive protein higher than 0.5mg\u002FdL on the day of the injection.\n* Colour vision deficiency or colour-blindness","45 Years",{"count":386,"type":23},56,[60],"Short-chain fatty acids (SCFAs) are substances produced by gut bacteria when they ferment dietary fiber. They can act as signals between the gut and the brain and may help regulate the body's immune and stress responses. Earlier work has shown that delivering SCFAs to the colon can lower the stress hormone response to a mental stress task in healthy people, and laboratory studies suggest SCFAs can reduce inflammation. However, it is not yet known whether SCFAs can reduce inflammation in humans, or whether doing so protects mental performance.\n\nThis study uses a controlled, acute, and short-lasting challenge. Healthy adults receive a single, low dose of a bacterial substance called lipopolysaccharide (LPS) through a vein. LPS briefly activates the immune system and causes mild, flu-like symptoms (such as fatigue, headache, and feeling unwell) that pass on their own within a few hours. It does not cause a real infection.\n\nParticipants are randomly assigned to take either SCFA capsules or inactive placebo capsules on the morning of the test day, before the LPS challenge. Neither the participants, the researchers running the visit, nor the researchers analyzing the results know who received which capsules until the study is complete (triple-blind).\n\nThe main goal of the study is to test whether SCFAs, compared with placebo, reduce the inflammatory response to LPS, measured by markers of inflammation in the blood. The study also examines whether SCFAs reduce the associated sickness symptoms and whether they protect performance on tasks that measure core executive functions: the ability to keep relevant information in mind (working memory), the ability to hold back automatic responses or thoughts (inhibition), and the ability to switch flexibly between tasks or rules (cognitive flexibility). Blood, saliva, and stool samples are collected to measure inflammation markers, SCFA levels, stress hormones, and gut bacteria.\n\nParticipants attend a screening visit, a test day with monitoring for several hours, and a short follow-up visit the next day.",[390,27,391],"Endotoxemia","Executive Function (Cognition)",[393,394,395,396,397,398,399,400,401,402,107,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417],"scfa","short-chain fatty acids","butyrate","proprionate","acetate","lypopolysaccharide","lps","endotoxemia","lps challenge","experimental","experimental inflammation","experimental endotoxemia","systemic inflammation","gut-brain axis","microbiota","microbiota-gut-brain axis","executive function","working memory","inhibition","cognitive inhibition","response inhibition","cognitive flexibility","task switching","healthy volunteers","sickness behaviour","2026-07-14",{"date":339,"type":37},{"date":421,"type":37},"2025-10-24",{"date":423,"type":23},"2027-03-30",{"name":425,"class":79},"Universitaire Ziekenhuizen KU Leuven",{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":58,"phases":434,"briefSummary":435,"conditions":436,"keywords":440,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":451,"leadSponsor":453,"locationsCount":45},"100647587","pumpkin-seed-oil-as-a-nutraceutical-for-hemodialysis-patients-100647587","NCT07710183","Pumpkin Seed Oil as a Nutraceutical for Hemodialysis Patients","Potential Role of Pumpkin Seed Oil as a Nutraceutical on the Clinical and Biochemical Outcomes in Hemodialysis Patients","Inclusion Criteria:\n\n* End-stage renal disease (ESRD) on hemodialysis for more than 6 months, on a constant dialysis program.\n* Hemodynamically stable (no recent hospitalization for infections, cardiovascular events, or major surgery within the past 3 months).\n* No active acute infections.\n* Serum albumin ≥ 3.0 g\u002FdL.\n\nExclusion Criteria:\n\n* Regular intake of dietary supplements (e.g., omega-3, antioxidants) for at least one month prior to enrollment.\n* Autoimmune disease, liver disease, cancer, or acquired immunodeficiency syndrome (AIDS).\n* Known sensitivity\u002Fallergy to pumpkin seed oil.\n* Current use of lipid-lowering agents.\n* Diabetes mellitus.\n* Current use of anticoagulants (warfarin, direct oral anticoagulants).\n* Current use of immunosuppressants, corticosteroids, or anti-inflammatory drugs.\n* Pregnant or breastfeeding women.\n* Residual kidney function (urine output \\> 200 mL\u002Fday).",{"count":150,"type":23},[60],"Patients with end-stage renal disease (ESRD) on maintenance hemodialysis experience chronic systemic inflammation, oxidative stress, and dyslipidemia, which together drive much of the excess cardiovascular morbidity and mortality seen in this population. Pumpkin seed oil is a nutraceutical rich in polyunsaturated fatty acids, phytosterols,and tocopherols, with documented antioxidant, anti-inflammatory, and antihyperlipidemic properties in preclinical and limited clinical studies. This study investigates the potential role of pumpkin seed oil as a nutraceutical on the clinical and biochemical outcomes of hemodialysis patients. It is a randomized, open-label, prospective interventional study in which daily oral supplementation with pumpkin seed oil (1000 mg once daily) for 3 months is evaluated against usual care. Eighty-five participants will be assigned to either an intervention group (n=45, pumpkin seed oil 1000 mg\u002Fday plus usual care) or a control group (n=40, usual care only). The biochemical outcomes assessed are changes in serum interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), soluble vascular cell adhesion molecule-1 (sVCAM-1), lipid profile, malondialdehyde (MDA), and superoxide dismutase (SOD) from baseline to the end of the 3-month follow-up period. The study is being conducted at the Hemodialysis Center, Al-Karama Teaching Hospital, Iraq",[437,438,27,439],"End Stage Renal Disease","Chronic Kidney Disease Requiring Chronic Dialysis","Oxidative Stress",[441,252,442,443,444,445,446,447],"Pumpkin seed oil","IL-6","hsCRP","sVCAM-1","Malondialdehyde","Superoxide dismutase","Lipid profile","2026-07-13",{"date":370,"type":37},{"date":339,"type":23},{"date":452,"type":23},"2027-04-01",{"name":454,"class":79},"Al-Mustansiriyah University",{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":200,"enrollmentInfo":462,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":45},"100242677","oxidative-stress-and-inflammatory-biomarkers-in-gaucher-disease-100242677","NCT02437396","Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease","Novel Inflammatory Biomarkers Complement 5A and Hepcidin in Patients With Gaucher Disease (GD)","Inclusion criteria:\n\n1. All participants must be 18 years or older.\n2. All enrollees must understand and cooperate with requirements of the study in the opinion of the investigators and must be able to provide written informed consent.\n3. Individuals with Gaucher disease who are medically stable for participation in study in the opinion of the investigator.\n4. GD subjects must be stable on a specific ERT and\u002For SRT therapy at a specific dose (for e.g. on a units\u002Fkg basis) for at least 2 years or be naïve to these therapies (no therapy for 2 years).\n5. GD1 patients, who have had a change in therapy i.e. a change in dose or switch from one drug to another, can be enrolled after at least 6 months have elapsed since the change and is considered stable in the opinion of the clinician providing care to the patient.\n6. All participants must not have taken antioxidants coenzyme Q-10, vitamin C, or vitamin E for 3 weeks prior to the study.\n\nExclusion Criteria:\n\n1. Medically unstable conditions in any group as determined by the investigators\n2. Concurrent disease; medical condition; or an extenuating circumstance that, in the opinion of the investigator, might compromise subject safety, study compliance, completion of the study, or the integrity of the data collected for the study.\n3. Females who are pregnant or lactating or of child-bearing age who are not using acceptable forms of contraception\n4. History of asthma that is presently being treated\n5. Subjects who cannot or are unwilling to have blood drawn\n6. Unable to adhere to study protocol for whatever reason",{"count":463,"type":23},34,"The objective of this study is to evaluate oxidative stress and\u002For inflammation in patients with Gaucher disease type I using a series of biomarkers and correlate with measurements of currently used diagnostic biomarkers.",[466,439,27],"Gaucher Disease Type I","2026-07-10",{"date":448,"type":37},{"date":470,"type":37},"2015-10",{"date":472,"type":23},"2026-10-30",{"name":474,"class":79},"University of Minnesota",{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":18,"minAge":482,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":58,"phases":485,"briefSummary":487,"conditions":488,"keywords":4,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":45},"100645981","early-phase-1-metformin-and-aclr-muscle-recovery-100645981","NCT07699367","Metformin and ACLR Muscle Recovery","Metformin and Muscle Recovery Following ACL Surgery","Inclusion Criteria:\n\n1. Age between 40y and older\n2. BMI: \\\u003C30 kg\u002Fm2\n3. Full thickness ACL tear\n4. Less than 6 months between ACL injury and scheduled ACLR\n\nExclusion Criteria:\n\n1. Prior ACL tear in limb scheduled for reconstruction or current bilateral ACL tear\n2. Total knee dislocation\n3. Anticipated quadriceps ACLR grafts\n4. Current infection near the lower limb\n5. Inability to attend physical therapy sessions\n6. Post-operative loading restrictions\n7. History of cardiovascular disease (e.g., CHF, CAD, MI, CVA)\n8. History of endocrine or metabolic disease such as hypo\u002Fhyperthyroidism and diabetes (Treated hypo\u002Fhyperthyroid for at least 6 months will be permitted)\n9. History of stroke with motor disability\n10. History of respiratory disease (acute upper respiratory infection, history of chronic lung disease)\n11. Self-reported pregnancy\n12. Bleeding disorder\n13. Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators)\n14. Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma\n15. Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular\u002Ftopical\u002Finhaled therapeutic or physiologic doses of corticosteroids will be permitted)\n16. Androgens or growth hormone within 6 months of enrollment and for study duration (topical physiologic androgen replacement will be permitted)\n17. Currently taking estrogen products (topical estrogen products will be permitted)\n18. Taking anticoagulant medication (warfarin\u002FCoumadin, heparin) that may complicate the muscle biopsy\n19. Any staff members who report directly to the principal investigators","40 Years",{"count":484,"type":23},40,[486],"EARLY_PHASE1","The purpose of this research study is to determine if Metformin taken after anterior cruciate ligament reconstruction (ACLR) surgery can decrease muscle fibrosis, cellular senescence and improve leg strength. ACL injury and surgery increase muscle collagen content and inflammation which slows the recovery of muscle and function and ultimately impacts the quality of life. Individuals enrolled in the study will be randomized to receive metformin (or placebo) for 4 months after surgery. The investigators will measure muscle strength and inflammatory markers in muscle biopsy samples after the intervention period. Investigators will also follow up with participants 8 months later to determine the lasting effects of the intervention.",[489,27,490],"Atrophy","Weakness, Muscle","2026-07-09",{"date":448,"type":37},{"date":494,"type":23},"2026-11-01",{"date":496,"type":23},"2032-10-01",{"name":498,"class":79},"University of Utah",{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":127,"enrollmentInfo":506,"targetDuration":4,"studyType":58,"phases":507,"briefSummary":508,"conditions":509,"keywords":4,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":514,"leadSponsor":516,"locationsCount":4},"100526387","comparing-effects-of-fermented-and-unfermented-pulses-and-gut-microbiota-100526387","NCT06134076","Comparing Effects of Fermented and Unfermented Pulses and Gut Microbiota","Impact of Fermented Pulses on Inflammation and the Gut Microbiota","Inclusion Criteria:\n\n* Healthy adults\n\nExclusion Criteria:\n\n* Taken antibiotics within the past month\n* Taking any medication for the management of diabetes or obesity\n* Are pregnant\n* BMI \\> 24.9\n* Allergies to pulses or any other meal components",{"count":173,"type":23},[60],"The goal of this clinical trial is to learn about the effects of consuming fermented pulses (certain types of legumes like chickpeas or lentils) in healthy people. The main questions it aims to answer are:\n\n1. How does consuming the fermented foods impact the gut microbiome?\n2. Does this interaction between the fermented foods and the gut microbiome affect inflammation?\n\nParticipants will be asked to consume two sets of prepared meals, one containing unfermented pulses, the other containing fermented pulses.\n\nResearchers will compare the gut microbiome and inflammation between these two diets.",[510,27],"Fermented Food","2026-07-08",{"date":467,"type":37},{"date":216,"type":23},{"date":515,"type":23},"2029-08",{"name":517,"class":79},"Penn State University",{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":148,"enrollmentInfo":526,"targetDuration":4,"studyType":58,"phases":527,"briefSummary":528,"conditions":529,"keywords":532,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":45},"100645108","randomized-cross-over-comparison-of-medium-cut-off-and-high-flux-hemodialysis-membranes-100645108","NCT07679763","Randomized Cross-Over Comparison of Medium Cut-Off and High-Flux Hemodialysis Membranes","Randomized Cross-Over Evaluation of Medium Cut-Off and High-Flux Hemodialysis Membranes on Inflammation and Cardiovascular Function in Maintenance Hemodialysis Patients","MCO-HD","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Receiving maintenance hemodialysis for at least 6 months.\n* Clinically stable and receiving thrice-weekly hemodialysis.\n* Able to comply with study procedures, questionnaires, and scheduled assessments.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Acute infection at screening or enrollment.\n* Major surgery within the previous 3 months.\n* Active malignancy requiring ongoing treatment.\n* Terminal illness with limited life expectancy.\n* Physical or cognitive impairment preventing completion of study procedures or questionnaires.\n* Inability or unwillingness to provide written informed consent.",{"count":173,"type":23},[60],"Patients receiving maintenance hemodialysis are at increased risk of cardiovascular disease, chronic inflammation, endothelial dysfunction, and impaired quality of life. Medium cut-Off (MCO) hemodialysis membranes have been developed to enhance the removal of middle-molecular-weight uremic toxins compared with conventional high-flux membranes, which may improve inflammatory status and cardiovascular health.\n\nThe aim of this study is to compare the effects of MCO and high-flux hemodialysis membranes on inflammatory biomarkers and cardiovascular function in adult patients receiving maintenance hemodialysis. The primary outcomes are changes in serum interleukin-6 (IL-6) and vascular cell adhesion molecule-1 (VCAM-1) levels. Secondary outcomes include arterial stiffness assessed by pulse wave velocity (PWV), body composition assessed by Body Composition Monitor (BCM), handgrip strength, and patient-reported outcomes including quality of life, pruritus, and pain scores.\n\nThis is a prospective, randomized, open-label, two-sequence, two-period crossover study conducted at Gazi University Faculty of Medicine. Thirty adult hemodialysis patients will be randomized to one of two treatment sequences. Participants in Sequence A will receive MCO dialysis membranes for the first 3 months followed by high-flux membranes for the next 3 months. Participants in Sequence B will receive high-flux membranes for the first 3 months followed by MCO membranes for the next 3 months. Blood samples and clinical assessments will be performed at baseline, month 3, and month 6.\n\nThe study is expected to provide evidence regarding the effects of different dialysis membrane technologies on inflammation and cardiovascular health and may contribute to optimizing membrane selection in routine hemodialysis practice.",[530,252,531,27],"End Stage Kidney Disease (ESKD)","Cardiovascular Diseases (CVD)",[533,534,535,536,537,27,538,539,540],"End-Stage Kidney Disease","High-Flux Hemodialysis","Medium Cut-Off Membrane","Interleukin-6","VCAM-1","Cardiovascular Function","Pulse Wave Velocity","Body Composition Monitor","2026-06-30",{"date":543,"type":37},"2026-07-01",{"date":545,"type":23},"2026-07",{"date":547,"type":23},"2027-01",{"name":549,"class":79},"Gazi University",{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":127,"enrollmentInfo":557,"targetDuration":4,"studyType":58,"phases":559,"briefSummary":561,"conditions":562,"keywords":564,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":45},"100590545","phase-3-study-on-ketorolac-for-improving-outcomes-and-prognosis-in-patients-with-stanford-type-a-aortic-dissection-100590545","NCT06968806","Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection","Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection -A Single-Center, Randomized, Double-Blind, Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients with Stanford Type A aortic dissection confirmed by imaging and scheduled for emergency surgery.\n\nAged between 18 and 65 years.\n\nSigned informed consent.\n\nExclusion Criteria:\n\n* Patients who are unable to eat independently or require prolonged fasting.\n\nHistory of malignant tumors.\n\nBody weight \\\u003C50 kg.\n\nTraumatic aortic dissection.\n\nPatients with Marfan syndrome.\n\nUnstable vital signs requiring preoperative mechanical support or resuscitation (e.g., IABP \\[Intra-Aortic Balloon Pump\\], ECMO \\[Extracorporeal Membrane Oxygenation\\], LVAD \\[Left Ventricular Assist Device\\])\n\nPatients requiring preoperative endotracheal intubation.\n\nConsciousness impairment, central nervous system dysfunction, or evidence of cerebral malperfusion syndrome upon admission.\n\nPreoperative hematemesis, melena, fresh blood in stool, or symptoms of bowel dilation.\n\nClear evidence of limb malperfusion before surgery.\n\nPresence of organ malperfusion syndrome.\n\nPatients requiring interventional procedures to relieve organ malperfusion before surgery.\n\nHistory of gastrointestinal ulcers or chronic gastrointestinal inflammatory diseases.\n\nHistory of dialysis or renal insufficiency before admission.\n\nHistory of liver disease.\n\nAllergy to ketorolac tromethamine, aspirin, or other nonsteroidal anti-inflammatory drugs (NSAIDs).\n\nChronic inflammatory diseases, autoimmune diseases, or long-term use of steroids or NSAIDs for other reasons.\n\nAbsence of cerebral perfusion during deep hypothermic circulatory arrest.\n\nHistory of major surgery or acute myocardial infarction within 90 days.\n\nHistory of cardiac or major vascular surgery.\n\nPregnant or lactating women.\n\nPatients who refuse to participate in this clinical trial or decline to sign the informed consent form.\n\nAny other conditions deemed unsuitable for participation by the investigator.",{"count":558,"type":23},360,[560],"PHASE3","This multicenter, randomized, double-blind, placebo-controlled trial evaluates the efficacy and safety of ketorolac in 360 patients with Stanford Type A aortic dissection, conducted between 2025 and 2027. Participants will receive either ketorolac (60 mg intramuscularly \\[IM\\] preoperatively and 30 mg twice daily \\[BID\\] for two days postoperatively) or placebo in addition to standard care. Study outcomes include composite clinical endpoints, postoperative complications, and adverse events, which will be assessed through clinical evaluations, laboratory testing, and imaging studies at predefined intervals up to 90 days. The objective of this trial is to determine whether perioperative administration of ketorolac improves clinical outcomes in this patient population.",[563,27],"Aortic Dissection",[27,563,565],"Ketorolac","2026-06-19",{"date":568,"type":37},"2026-06-23",{"date":570,"type":37},"2025-10-27",{"date":572,"type":23},"2028-09-01",{"name":574,"class":79},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":4,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":582,"targetDuration":584,"studyType":24,"phases":4,"briefSummary":585,"conditions":586,"keywords":4,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":4},"100642567","effects-of-icosapent-ethyl-on-coronary-plaque-inflammation-and-ventricular-remodeling-100642567","NCT07641257","Effects of Icosapent Ethyl on Coronary Plaque, Inflammation, and Ventricular Remodeling","Impact of Icosapent Ethyl on Ventricular Remodeling, Inflammation, and Coronary Plaque Stability in Patients With Acute or Chronic Coronary Syndrome: A Prospective, Observational, Real-World Study","Inclusion Criteria:\n\n* Age 18 years and older, of any sex.\n\n  * Definite diagnosis of chronic coronary syndrome (CCS) according to the Chinese Guidelines for the Diagnosis and Management of Patients with Chronic Coronary Syndrome, or acute coronary syndrome (ACS) according to the 2025 ACC\u002FAHA\u002FACEP\u002FNAEMSP\u002FSACI Guideline for the Management of Acute Coronary Syndromes.\n  * Laboratory evaluation showing fasting triglycerides (TG) \\>= 1.7 mmol\u002FL.\n  * Ability to fully understand the study purpose, voluntary participation, and provision of signed written informed consent.\n\nExclusion Criteria:\n\n* Women who are planning a pregnancy, currently pregnant, or lactating.\n\n  * Known hypersensitivity or allergic reaction to the active ingredient of icosapent ethyl (IPE) or any of its excipients (applicable to patients in the exposure cohort).\n  * Diagnosed with major life-threatening conditions such as malignant tumors, end-stage lung disease, or advanced neurodegenerative diseases, with a life expectancy of less than 12 months.\n  * Concurrent participation in any other interventional clinical trial involving investigational drugs or medical devices.\n  * Any other condition or severe non-compliance that, in the judgment of the investigator, makes the patient unsuitable for enrollment in this study.",{"count":583,"type":23},420,"12 Months","Even with standard treatments like statins, patients with coronary artery disease often face a residual risk of further heart events. This risk is largely driven by ongoing inflammation and unstable fatty plaques in the heart's blood vessels. Icosapent ethyl (IPE) is a highly purified prescription medication known to improve cardiovascular outcomes, but its detailed effects on the heart's structure and inflammation in everyday clinical practice need further exploration.\n\nThis study is a prospective, observational, real-world study designed to evaluate the effectiveness of IPE in patients with Acute Coronary Syndrome (ACS) or Chronic Coronary Syndrome (CCS). The study plans to enroll 420 patients who will be followed for 12 months. Based on their routine clinical prescriptions, participants will be grouped into a control group (receiving standard cardiovascular care, including statins) and an exposure group (receiving standard care plus IPE).\n\nThroughout the 1-year follow-up, researchers will conduct regular blood tests and advanced heart imaging. The main goal is to determine if adding IPE to standard therapy leads to a more significant reduction in inflammation. Additionally, the study will observe how IPE affects the stability of coronary plaques and the healing process of ventricular remodeling in a real-world clinical setting.",[587,588,589,590,591,27],"Acute Coronary Syndromes (ACS)","Chronic Coronary Syndrome","Coronary Artery Disease","Atherosclerosis Cardiovascular Disease","Ventricular Remodeling","2026-06-08",{"date":594,"type":37},"2026-06-11",{"date":596,"type":23},"2026-05-30",{"date":598,"type":23},"2029-05-30",{"name":600,"class":79},"Ruijin Hospital",{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":17,"sex":609,"minAge":384,"maxAge":127,"enrollmentInfo":610,"targetDuration":4,"studyType":58,"phases":612,"briefSummary":613,"conditions":614,"keywords":617,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":631,"locationsCount":45},"100556603","nitrate-exercise-and-vascular-function-in-midlife-women-100556603","NCT06527248","Nitrate, Exercise and Vascular Function in Midlife Women","Effects of Dietary Nitrate From Beetroot Juice on Vascular Function and Adaptations to Exercise Training in Postmenopausal Women: a Randomized, Placebo-controlled Study","Women's-Beet","Inclusion Criteria:\n\n* Postmenopausal women (amenorrhoeic ≥1 year), between the ages of 45 and 65 years, inclusive, who are either normotensive or are medically treated for stage 1 hypertension\n* Written informed consent\n\nExclusion Criteria:\n\n* Current or recent (within previous 3 months) engagement in exercise training (i.e., planned, structured, and regular exercise) with an average net exercise time of \\>2 hours per week\n* Above-average cardiorespiratory fitness levels (i.e., a V̇O2 max max above the 75th percentile of age- and sex-specific normative data: ≥43 mL\u002Fkg\u002Fmin for women aged 45-49 years, ≥38 mL\u002Fkg\u002Fmin for women aged 50-59 years, ≥35 mL\u002Fkg\u002Fmin for women aged 60-65 years)\n* Any evidence of acute or chronic diseases such as symptomatic cardiovascular or peripheral vascular disease, moderate or severe chronic kidney disease (estimated glomerular filtration rate (GFR) \\\u003C50 mL\u002Fmin), pulmonary, neural, or musculoskeletal disease, osteoporotic fractures, cancer, or type 1 or 2 diabetes mellitus\n* Fasting glucose \\>7.0 mmol\u002FL or HbA1c \\> 6.5 rel. %\n* BMI \\\u003C18.5 kg\u002Fm2 or \\>30kg\u002Fm2\n* A mean 24-hour ambulatory systolic\u002Fdiastolic blood pressure of ≥130\u002F80 mm Hg\n* Irregular resting electrocardiography (ECG)\n* Inability to perform physical exercise\n* Abnormal cardiovascular responses during the baseline V ̇O2 max test, including symptoms, ECG abnormalities, arrhythmias, or exaggerated blood pressure responses\n* Current or recent (\\\u003C12 months) oestrogen-based hormone-replacement therapy\n* Chronic use of nitric oxide (NO) donors, organic nitrites\u002Fnitrates, Ticagrelor, sodium-glucose cotransporter 2 (SGLT2) inhibitors, high-dose statins (i.e., Simvastatin \\>40mg\u002Fday, Atorvastatin \\>20mg\u002Fday, Rosuvastatin \\>10mg\u002Fday), acetylsalicylic acid \\>100mg\u002Fday, non-steroidal anti-inflammatory drugs (NSAID)\n* A change in drug therapy likely to influence major outcomes within the previous 2 months, or likelihood that drug therapy would change during the study\n* Use of antibiotics (within previous 2 months)\n* Use of antibacterial mouthwash (volunteers willing to cease using antibacterial mouthwash for a period of 4 weeks before randomization will be included)\n* Being vegan or vegetarian or consumption of \\>5 serves of vegetables per day\n* Current or recent (within previous 6 months) significant (\\>6%) loss or gain of body weight\n* Current or recent (\\\u003C12 months) regular smoking of \\>5 cigarettes per day\n* Alcohol intake of \\>70 g per week and\u002For binge drinking behaviour\n* Inability or unwillingness to follow the study protocol","FEMALE",{"count":611,"type":23},54,[60],"The purpose of this clinical study in women after menopause is to investigate whether the daily intake of nitrate from beetroot juice over 12 weeks enhances the positive effect of exercise training on vascular function, blood pressure and physical performance.\n\nThe risk of cardiovascular diseases (CVD) increases with advancing age and women are particularly affected. In women, the decline in the sex hormone oestrogen in the blood circulation with menopause contributes to impaired vascular function and an increased CVD risk; in part through increased inflammatory processes, oxidative stress, and a reduced body's own production of nitric oxide (NO). NO is a signaling molecule that is important for vascular function. Endurance-based exercise training is a key lifestyle strategy to prevent CVD. However, studies indicate that exercise is less effective in terms of its health-promoting adaptations in women after menopause as compared with men of similar age.\n\nThis study investigates the effect of exercise training in combination with the intake of nitrate-rich beetroot juice on functions of the cardiovascular system. Nitrate is a nitrogen compound that is found naturally in plant foods (e.g. beetroot juice) and is converted to NO in the human body. Results of previous studies indicate vasodilatory, blood pressure-lowering and performance-enhancing effects as well as positive influences on inflammatory processes and oxidative stress following nitrate intake. The hypothesis is that nitrate intake concomitant to training promotes training adaptations and further improves vascular function, blood pressure and physical performance compared to training without nitrate intake.\n\nFor the study, 54 untrained postmenopausal women (with the ages between 45 and 65 years) will be recruited and randomly allocated into two groups. Both groups will undergo 12 weeks of endurance-based exercise training. One group will receive nitrate-rich beetroot juice, and the other nitrate-depleted beetroot juice (as placebo). Vascular function, blood pressure, maximum oxygen uptake, and blood biomarkers for nitrate metabolism, inflammation status and oxidative stress will be examined.\n\nThe anticipated study results will provide new insights into whether nitrate as a 'training adjunct' improves health-promoting training adaptations in women after menopause. The overall aim is to improve the cardiovascular health and performance of middle-aged women and reduce their increased CVD risk.",[615,616,64,27],"Healthy","Menopause",[618,619,620,621,622,623],"Women after menopause","Vascular function","Exercise training responsiveness","Cardiovascular health","Dietary nitrate-nitrite-nitric oxide-pathway","Beetroot juice","2026-06-03",{"date":626,"type":37},"2026-06-05",{"date":628,"type":37},"2025-03-31",{"date":630,"type":23},"2027-03",{"name":632,"class":79},"University of Vienna",{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":637,"acronym":4,"eligibilityCriteria":638,"healthyVolunteers":17,"sex":18,"minAge":639,"maxAge":127,"enrollmentInfo":640,"targetDuration":4,"studyType":58,"phases":641,"briefSummary":642,"conditions":643,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":651,"locationsCount":45},"100400646","pilot-study-evaluating-the-impact-of-stress-reduction-on-atherosclerotic--heart-and-mind-study-100400646","NCT04496947","Pilot Study Evaluating the Impact of Stress Reduction on Atherosclerotic : Heart and Mind Study","Inclusion Criteria:\n\n* • Aged between 30-65 years\n\n  * Identifies as having increased levels of stress and\u002For has a Perceived Stress Scale (PSS) score \\>5 at baseline, and is interested in participating\n\nExclusion Criteria:\n\n* Perceived Stress Scale (PSS) score \\\u003C6","30 Years",{"count":173,"type":23},[60],"The plot study aims to evaluate the effect of 8 weeks of stress reducing intervention on atherosclerotic plaque inflammation in adults, as quantified by positron emission tomography (PET) with fluorine-2-deoxy-D-glucose (FDG) in individuals with increased psychosocial stress.",[644,645,27],"Atherosclerosis","Stress","2026-05-31",{"date":624,"type":37},{"date":649,"type":37},"2018-09-01",{"date":76,"type":23},{"name":652,"class":79},"Massachusetts General Hospital",{"id":654,"slug":655,"hasResults":12,"nctId":656,"briefTitle":657,"officialTitle":658,"acronym":659,"eligibilityCriteria":660,"healthyVolunteers":17,"sex":609,"minAge":19,"maxAge":661,"enrollmentInfo":662,"targetDuration":4,"studyType":58,"phases":664,"briefSummary":666,"conditions":667,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":679,"lastUpdatePostDateStruct":680,"startDateStruct":682,"completionDateStruct":684,"leadSponsor":686,"locationsCount":45},"100640820","phase-1-hormones-outcomes-and-pain-pathways-in-exercise-study-100640820","NCT07579182","Hormones, Outcomes, and Pain Pathways in Exercise Study","Mechanical and Non-mechanical Contributions to Chronic Neck, Shoulder, Arm, and Back Pain in Full-busted Women","HOPE","Inclusion Criteria:\n\n1. Able to provide informed consent\n2. Age of 18 to 60 years\n3. Assigned female sex at birth\n4. Right-handed by self-declaration\n5. Willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size between 32-40\"\n7. International Physical Activity Questionnaire - Short Form (IPAQ-SF) score of 2 or higher\n8. An answer of \"NO\" to any item of the general health questions of the PARQ+\n9. No history of surgery to the: back, neck, or shoulders or joint replacement\n10. No history of implanted pacemakers or other stimulation devices\n11. No history of spinal cord injury (SCI)\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Age 17 years old or younger or 61 years or older\n3. Assigned male sex at birth\n4. Left-handed by self-declaration\n5. Not willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size greater than 40\" or less than 32\"\n7. IPAQ-SF score of 1 or lower\n8. An answer of \"YES\" to any item of the general health questions of the PARQ+\n9. History of limb amputation (upper or lower extremity)\n10. Presence of open pressure sores on the upper or lower extremities\n11. Currently pregnant or lactating\u002Fbreastfeeding\n12. History of surgery to the: back, neck, or shoulders or joint replacement\n13. History of breast cancer and\u002For mastectomy\n14. History of implanted pacemakers or other stimulation devices\n15. History of spinal cord injury (SCI)\n16. History of joint disease including osteoarthritis and\u002For Rheumatoid Arthritis\n17. History of the following neurological diseases: Cerebrovascular accident (CVA, stroke), Alzheimer's Disease (AD), Dementia (of any form), Huntington's Disease, Traumatic Brain Injury (TBI), Spinal cord injury (SCI), Multiple Sclerosis (MS), Parkinson's Disease (PD), Polio, Paraproteinaemic Demyelinating Neuropathy (PDN) and\u002For Monoclonal Gammopathy of Undetermined Significance (MGUS), Myasthenia Gravis, Muscular Dystrophy, Guillain-Barré Syndrome, Scoliosis, Charcot-Marie-Tooth Disorder or other hereditary neuropathies\n\nAdditional Inclusion Criteria for Intervention Group:\n\na. Self-declared breast size of D-I cup (US sizes: D, E, F, G, H)\n\nAdditional Inclusion Criteria for the Control Group:\n\na. Self-declared breast size of A-C cup (US sizes: AA, A, B, C)","60 Years",{"count":663,"type":23},140,[665],"PHASE1","The goal of the proposed project is to evaluate a mechanical intervention (sports bras designed specifically for full busted women) to alleviate neck, shoulder, arm, and back pain in full-busted women and investigate the contribution of non-mechanical pathways associated with this type of pain in women. Specifically, the investigators will investigate how sex-hormones, inflammation, and remapping of specific regions of the brain contribute to the manifestation of neck, shoulder, arm, and back pain in full-busted women across the lifespan.",[668,669,670,671,672,673,674,206,675,27,676,677,678],"Breast Pain","Mastalgia","Back Pain","Back Pain, Low","Neck Pain","Chest Pain","Activity, Motor","Weight, Body","Gonadal Steroid Hormones","Neuronal Plasticity","Neuromuscular Manifestations","2026-05-28",{"date":681,"type":37},"2026-06-02",{"date":683,"type":37},"2026-05-17",{"date":685,"type":23},"2029-09",{"name":687,"class":79},"University of Houston",{"id":689,"slug":690,"hasResults":12,"nctId":691,"briefTitle":692,"officialTitle":692,"acronym":4,"eligibilityCriteria":693,"healthyVolunteers":17,"sex":18,"minAge":482,"maxAge":4,"enrollmentInfo":694,"targetDuration":4,"studyType":58,"phases":695,"briefSummary":696,"conditions":697,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":700,"lastUpdatePostDateStruct":701,"startDateStruct":703,"completionDateStruct":705,"leadSponsor":706,"locationsCount":45},"100640688","clinical-trial-evaluating-the-impact-of-a-dietary-supplement-containing-humic-and-fulvic-acid-on-epigenetic-markers-of-biological-age-detoxification-inflammation-and-oxidative-stress-100640688","NCT07579845","Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress","Inclusion Criteria:\n\n1. Adult females or males age ≥ 40 years\n2. Ability to read and speak English\n\nExclusion Criteria:\n\n1. Current use of a dietary supplement containing fulvic or humic acid\n2. Current use of other binder dietary supplements, including activated charcoal, modified citrus pectin, bentonite clay, or chlorella\n3. Known allergies to any ingredients in the product\n4. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks\n5. Current diagnosis of a chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol\n6. Participants unable to provide consent",{"count":248,"type":23},[60],"The primary purpose of this study is to evaluate the impact of BioToxin Binder, a commercially available dietary supplement containing humic and fulvic acid, on markers of biologic age, detoxification, inflammation, oxidative stress, and related markers among generally healthy adults.",[698,27,699],"Detoxification","Biological Aging","2026-05-27",{"date":702,"type":37},"2026-05-29",{"date":704,"type":37},"2026-05-05",{"date":291,"type":23},{"name":707,"class":708},"OvationLab","NETWORK"]